Use of cellular and plasma apheresis in the critically ill patient: Part 1: Technical and physiological considerations

Journal of Intensive Care Medicine

Volumn 20, Issue 1, 2005, Pages 18-27

  Linenberger, Michael L ^a,c,d   Price, Thomas H ^b,c  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Apheresis and Cellular Therapy   (United States)

Author keywords

Apheresis; Leukapheresis; Plateletpheresis; Red cell exchange; Therapeutic plasma exchange

Indexed keywords

ACID CITRATE DEXTROSE; ANTICOAGULANT AGENT; CITRIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; IMMUNOGLOBULIN; STAPHYLOCOCCUS PROTEIN A;

APHERESIS; AUTOIMMUNE DISEASE; BLOOD; BLOOD TRANSFUSION; BLOOD VOLUME; CRITICALLY ILL PATIENT; DEPLETION; DISTAL PARESTHESIA; ERYTHROCYTE; EXTRACORPOREAL CIRCULATION; FLUID BALANCE; HEMATOLOGIC DISEASE; HEMODYNAMICS; HEMOSTASIS; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; MUSCLE SPASM; MUSCLE TWITCH; NAUSEA; NEUROLOGIC DISEASE; PARESTHESIA; PATIENT CARE; PLASMA; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SIDE EFFECT; TETANY; THROMBOCYTOPHERESIS; VASCULAR ACCESS; CATHETERIZATION; CYTAPHERESIS; ELECTROLYTE BALANCE; INSTRUMENTATION; METHODOLOGY;

ANTICOAGULANTS; BLOOD VOLUME DETERMINATION; CATHETERIZATION; CYTAPHERESIS; HEMOSTASIS; HUMANS; PLASMAPHERESIS; WATER-ELECTROLYTE BALANCE;

EID: 16244372390     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1177/0885066604271394     Document Type: Review

References (31)

1. Smith JW, Weinstein R, for the AABB Hemapheresis Committee KL. Therapeutic apheresis: a summary of current indication categories endorsed by the American Association of Blood Banks and the American Society for Apheresis. Transfusion. 2003;43:820-822.
2. Burgstaler EA. Current instrumentation for apheresis. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed. Bethesda, Md: American Association of Blood Banks; 2003:95-130.
3. Madore F. Plasmapheresis. Technical aspects and indications. Crit Care Clin. 2002;18:375-392.
4. Siami GA, Siami FS. Membrane plasmapheresis in the United States: a review over the last 20 years. Ther Apher. 2001;5:315-320.
5. Drew MJ. Plasmapheresis in the dysproteinemias. Ther Apher. 2002;6:45-52.
6. Hirasawa H, Sugai T, Oda S, et al. Efficacy and limitation of apheresis therapy in critical care. Ther Apher. 1997;1:228-232.
7. Hart GK. Plasmapheresis in intensive care. Part 2 of 2: indications for plasmapheresis and plasma exchange in the intensive care unit. Intensive Care World. 1990;7:80-84.
8. Schmidt J, Mann S, Mohr VD, Lambert R, Firla U, Zirngibl H. Plasmapheresis combined with continuous venovenous hemofiltration in surgical patients with sepsis. Intensive Care Med. 2000;26:532-537.
9. Reeves JH, Butt WW, Shann F, et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med. 1999;27:2096-2104.
10. Hart GK. Plasmapheresis in intensive care. Part 1 of 2: history, techniques and complications. Intensive Care World. 1990;7:21-25.
11. Kodama M, Hanasawa K, Tani T. Blood purification for critical care medicine: endotoxin adsorption. Ther Apher. 1997;1:224-227.
12. Yang KS, Kenpe K, Yamaji K, Tsuda H, Hasimoto H. Plasma adsorption in critical care. Ther Apher. 2002;6:184-188.
13. Stegmayr BG. Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. Ther Apher. 2001;5:123-127.
14. Vamvakas EC, Pineda AA. Selective extraction of plasma constituents. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed. Bethesda, Md: American Association of Blood Banks; 2003:437-476.
15. Schonermarck U, Bosch T. Vascular access for apheresis in intensive care patients. Ther Apher Dial. 2003;7:215-220.
16. Sadler DJ, Saliken JC, So CB, Gray RR. Apheresis: another indication for radiologically placed central venous catheters. Can Assoc Radiol J. 1999;50:177-181.
17. Apsner R, Schwarzenhofer M, Derfler K, Zauner C, Ratheiser K, Kranz A. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr. 1997;109:123-127.
18. Crookston KP, Simon TL. Physiology of apheresis. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed. Bethesda, Md: American Association of Blood Banks; 2003:71-94.
19. McLeod BC, Sniecinski I, Ciavarella D, et al. Frequency of immediate adverse effects associated with therapeutic apheresis. Transfusion. 1999;39:282-288.
20. Korach JM, Berger P, Giraud C, Le Perff-Desman C, Chillet P. Role of replacement fluids in the immediate complications of plasma exchange. French Registry Cooperative Group. Intensive Care Med. 1998;24:452-458.
21. Schlenke P, Frohn C, Steinhardt MM, Kirchner H, Kluter H. Clinically relevant hypokalaemia, hypocalcaemia, and loss of hemoglobin and platelets during stem cell apheresis. J Clin Apheresis. 2000;15:230-235.
22. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis. 1994; 23:817-827.
23. Weinstein R. Hypocalcemic toxicity and atypical reactions in therapeutic plasma exchange. J Clin Apheresis. 2001;16:210-211.
24. Jones HG, Bandarenko N. Management of the therapeutic apheresis patient. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed. Bethesda, Md: American Association of Blood Banks; 2003:253-282.
25. Goodnough LT, Brecher ME, Kanter MH, Au Buchon JP. Transfusion medicine. First of two parts-blood transfusion. N Engl J Med. 1999;340:438-447.
26. Weinstein R. Basic principles of therapeutic blood exchange. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed. Bethesda, Md: American Association of Blood Banks; 2003:295-320.
27. Brecher ME. Plasma exchange: why we do what we do. J Clin Apheresis. 2002;17:207-211.
28. McLeod BC. Therapeutic plasma exchange in neurologic disorders. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed. Bethesda, Md: American Association of Blood Banks; 2003:321-344.
29. Dau PC. Immunologic rebound. J Clin Apheresis. 1995;10:210-217.
30. Hester J. Therapeutic cell depletion. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed. Bethesda, Md: American Association of Blood Banks; 2003:283-294.
31. Pepkowitz S. Red cell exchange and other therapeutic alterations of red cell mass. In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice. 2nd ed. Bethesda, Md: American Association of Blood Banks; 2003:411-436.